• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy Preps for FDA at Indian Facility

      Posted AtFiercepharmamanufacturing.com

      As Daiichi Sankyo's Ranbaxy unit awaits FDA inspection of its Dewas, India, facility--a step toward resuming the export of drugs from the plant--the parent company's incoming CEO Joji Nakayama says he's confident a ban imposed by U.S. regulators will be lifted.

      The ban stretches back to 2008 when GMP violations at Dewas and the company's Paonta Sahib facility were compounded by falsified data, as we've reported [1]. The FDA ultimately blocked 30 of the company's generics from U.S. sales. And the regulator prohibited the drugmaker from introducing to the U.S. new drugs from the Paonta Sahib plant. The FDA has also stopped reviewing drug submissions that involve the plant.

      "Ranbaxy is experienced in making medicines at a lower cost and Daiichi Sankyo aims to take full advantage of it after the FDA issue is resolved," Nakayama says in a Bloomberg report.

      Nakayama's predecessor, Takashi Shoda, said in March that he expected the FDA import ban to be lifted by 2012. And U.K. and Australian regulators have recently approved drugs from the plant after a joint audit.

      June 16, 2010


      Share this Article!

    Back to top^